Venture round

Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares

Retrieved on: 
Monday, January 9, 2023

MONACO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today that the Company's Board of Directors has declared:

Key Points: 
  • MONACO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today that the Company's Board of Directors has declared:
    a cash dividend of $0.50 per share on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares (the “Series C Preferred Shares”) (NYSE: SB.PR.C) for the period from October 30, 2022 to January 29, 2023;
    a cash dividend of $0.50 per share on its 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares (the “Series D Preferred Shares”) (NYSE: SB.PR.D) for the period from October 30, 2022 to January 29, 2023.
  • Each dividend will be paid on January 30, 2023 to all shareholders of record as of January 20, 2023 of the Series C Preferred Shares and of the Series D Preferred Shares, respectively.
  • Dividends on the Series C and D Preferred Shares are payable quarterly in arrears on the 30th day (unless the 30th falls on a weekend or public holiday, in which case the payment date is moved to the next business day) of January, April, July and October of each year.
  • The declaration and payment of dividends, if any, will always be subject to the discretion of the Board of Directors of the Company, and will depend on, among other things, the Company’s earnings, financial condition and cash requirements and availability, the Company’s ability to obtain debt and equity financing on acceptable terms as contemplated by the Company’s growth and leverage strategies, the restrictive covenants in the Company’s existing and future debt instruments and global economic conditions.

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

Retrieved on: 
Thursday, January 5, 2023

Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.

Key Points: 
  • Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.
  • "After completing a successful $60 million Series B+ round at the end of 2020, we are thrilled to have well-recognized investors participate in our C/C+ round.
  • "The Series C/C+ financing is a significant milestone for HighTide.
  • It will enable us to move aggressively to accelerate the clinical and commercial development of our innovative pipeline and external business collaborations."

EQS-News: Heliad Equity Partners GmbH & Co. KGaA: Enpal closes its Series D round with €200 million in equity

Retrieved on: 
Sunday, January 22, 2023

EQS-News: Heliad Equity Partners GmbH & Co. KGaA

Key Points: 
  • EQS-News: Heliad Equity Partners GmbH & Co. KGaA
    Heliad Equity Partners GmbH & Co. KGaA: Enpal closes its Series D round with €200 million in equity
    The issuer is solely responsible for the content of this announcement.
  • Enpal closes its Series D round with €200 million in equity.
  • Frankfurt am Main, December 10, 2023 - Enpal, a portfolio company of Heliad Equity Partners GmbH & Co. KGaA (ISIN: DE000A0L1NN5), receives additional growth capital of €200 million.
  • The Series D financing round is led by TPG Rise Climate, one of the world's leading investors in renewable energy and climate tech.

EQS-News: Heliad Equity Partners GmbH & Co. KGaA: Razor Group has successfully closed their €70 Million Series C

Retrieved on: 
Sunday, January 22, 2023

EQS-News: Heliad Equity Partners GmbH & Co. KGaA

Key Points: 
  • EQS-News: Heliad Equity Partners GmbH & Co. KGaA
    Heliad Equity Partners GmbH & Co. KGaA: Razor Group has successfully closed their €70 Million Series C
    The issuer is solely responsible for the content of this announcement.
  • Razor Group receives €70 Million equity financing in Series C round.
  • Frankfurt am Main, January 2nd, 2023 – Razor Group ("Razor"), a portfolio company of Heliad Equity Partners GmbH & Co. KGaA (ISIN: DE000A0L1NN5), has raised €70 million in further equity as part of its Series C financing round.
  • Heliad invested a mid-single-digit million amount in August last year as part of the previous Series B round.

Arbor Realty Trust Declares Preferred Stock Dividends

Retrieved on: 
Tuesday, January 3, 2023

UNIONDALE, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Arbor Realty Trust, Inc. (NYSE: ABR), today announced that its Board of Directors has declared cash dividends on the Company's Series D, Series E, and Series F cumulative redeemable preferred stock of $0.3984375, $0.390625, and $0.390625 per share, respectively.

Key Points: 
  • UNIONDALE, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Arbor Realty Trust, Inc. (NYSE: ABR), today announced that its Board of Directors has declared cash dividends on the Company's Series D, Series E, and Series F cumulative redeemable preferred stock of $0.3984375, $0.390625, and $0.390625 per share, respectively.
  • The Series D, E, and F preferred stock dividends reflect accrued dividends from October 30, 2022 through January 29, 2023.
  • The dividends are payable on January 31, 2023 to preferred stockholders of record on January 15, 2023.

Costamare Inc. Declares Quarterly Dividend on Its Preferred and Common Stock

Retrieved on: 
Tuesday, January 3, 2023

MONACO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred Stock”) (NYSE: CMRE PR B), US $0.531250 per share on its 8.50% Series C Cumulative Redeemable Perpetual Preferred Stock (the “Series C Preferred Stock”) (NYSE: CMRE PR C), US $0.546875 per share on its 8.75% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”) (NYSE: CMRE PR D) and US $0.554688 per share on its 8.875% Series E Cumulative Redeemable Perpetual Preferred Stock (the “Series E Preferred Stock”) (NYSE: CMRE PR E).

Key Points: 
  • MONACO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred Stock”) (NYSE: CMRE PR B), US $0.531250 per share on its 8.50% Series C Cumulative Redeemable Perpetual Preferred Stock (the “Series C Preferred Stock”) (NYSE: CMRE PR C), US $0.546875 per share on its 8.75% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”) (NYSE: CMRE PR D) and US $0.554688 per share on its 8.875% Series E Cumulative Redeemable Perpetual Preferred Stock (the “Series E Preferred Stock”) (NYSE: CMRE PR E).
  • The dividend for the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock and the Series E Preferred Stock is for the period from October 15, 2022, to January 14, 2023.
  • The dividend will be paid on January 17, 2023 to all holders of record as of January 13, 2023 of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock.
  • The dividend for the common stock is payable on February 7, 2023, to holders of record of common stock as of January 20, 2023.

Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program

Retrieved on: 
Wednesday, December 21, 2022

CONSHOHOCKEN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments following the achievement of the clinical milestone under its Hercules Credit Facility.

Key Points: 
  • CONSHOHOCKEN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments following the achievement of the clinical milestone under its Hercules Credit Facility.
  • Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated: “The financings secured following the positive topline readout of our Phase 3 MAESTRO-NASH trial reflect the strong support that Madrigal has established with long-standing strategic and institutional investors.
  • The Series B is substantially identical to the Series A Convertible Preferred Stock issued by the Company in 2017, with the most significant difference being the current conversion price of $225 per common share.
  • The total number of shares of common stock (including common stock equivalents) sold through the ATM Sales and the Registered Direct Sales totaled 1,183,344 common equivalent shares.

Caban Systems Raises $51M Series B to Accelerate Growth

Retrieved on: 
Wednesday, January 4, 2023

BURLINGAME, Calif., Jan. 4, 2023 /PRNewswire/ -- Caban Systems , Inc. ("Caban"), a leader in next-generation renewable energy solutions for critical infrastructure, has raised $51M to accelerate its global expansion strategy.

Key Points: 
  • BURLINGAME, Calif., Jan. 4, 2023 /PRNewswire/ -- Caban Systems , Inc. ("Caban"), a leader in next-generation renewable energy solutions for critical infrastructure, has raised $51M to accelerate its global expansion strategy.
  • The Series B round was led by investor BCP Ventures with participation from Ontario Power Generation Pension Fund, Ember Infrastructure, Portfolia, and Inspiration Ventures.
  • The new funding enables Caban to scale domestic battery manufacturing capacity, broaden its product and service offerings, and expand into global markets.
  • "After a successful launch in Latin America, our Series B will allow us to grow our business globally."

Semperis Accelerates Adoption of Identity Threat Detection and Response in the Public Sector with Key Appointment

Retrieved on: 
Tuesday, December 20, 2022

The expansion of Semperis’ public sector program addresses the heightened need for identity-first security among state, local, and federal government organizations.

Key Points: 
  • The expansion of Semperis’ public sector program addresses the heightened need for identity-first security among state, local, and federal government organizations.
  • Ransomware attacks in the public sector can cause massive disruption, creating a sense of urgency.
  • In addition, public sector organizations are prime targets for cyberattacks because of common vulnerabilities, including legacy infrastructure, lack of identity security expertise, and limited resources.
  • Ransomware campaigns targeting public sector organizations have proliferated in recent years, spanning attacks on 911 call centers, public school systems, and utilities.

EnginZyme Raises €21 Million in Series B to Accelerate the Commercialisation of Its Cell-Free Biomanufacturing Technology

Retrieved on: 
Monday, December 19, 2022

EnginZyme, a green tech company developing biomanufacturing processes for the sustainable manufacturing of everyday products, announced today that it had raised €21 million in a Series B financing round.

Key Points: 
  • EnginZyme, a green tech company developing biomanufacturing processes for the sustainable manufacturing of everyday products, announced today that it had raised €21 million in a Series B financing round.
  • Its technology platform utilises nature’s catalysts, enzymes, combining the power of biology with the efficiency of the chemical industry in a best-of-both-worlds solution.
  • “This fundraising marks a pivotal moment for EnginZyme," said Dr. Karim Engelmark Cassimjee, CEO and co-founder of EnginZyme.
  • By replacing traditional fossil-based manufacturing with the patented cell-free technology platform, EnginZyme seeks to accelerate the shift toward the sustainable biomanufacturing of products that modern society relies on.